VRK3

VRK3 is a nuclear pseudokinase that functions primarily as a signaling scaffold to suppress ERK activity in the nucleus (PMID:19141289, PMID:16845380). Its crystal structure shows a degraded active site that cannot bind ATP, with surface residues conserved for protein–protein interactions, consistent with a scaffolding rather than canonical catalytic role (PMID:19141289). VRK3 directly binds the dual-specificity phosphatase VHR and enhances its phosphatase activity toward phospho-ERK independently of any kinase activity, forming a VHR–VRK3 complex that constitutes the phosphatase-active form regulating EGF-induced ERK signaling (PMID:16845380, PMID:18035061). This VHR-activating function is potentiated by CDK5-mediated phosphorylation of VRK3 at Ser108 under oxidative stress, which increases VRK3 affinity for VHR and confers neuroprotection against H2O2-induced apoptosis (PMID:27346674), and by VRK3-dependent nuclear localization of HSP70, which itself enhances VHR activity through direct interaction to limit excitotoxic ERK activation (PMID:27941812). Despite its degraded active site, VRK3 retains kinase activity toward the nuclear envelope protein BAF at Ser4 via an N-terminal regulatory region, driving BAF nucleo-cytoplasmic translocation and promoting cell cycle progression (PMID:25899223). Beyond these characterized roles, links to cell cycle regulators, circadian clock protein localization, and chromatin condensation are documented but mechanistically limited in the available corpus (PMID:28927264, PMID:28412365, PMID:37886173).

1. 2006 High

   Established VRK3's principal function by showing it acts as a kinase-independent scaffold that activates the VHR phosphatase to suppress nuclear ERK, reframing a putative kinase as a phosphatase regulator.

   Evidence Reciprocal Co-IP and in vitro phosphatase assays with recombinant VRK3 and kinase-dead mutant

   PMID:16845380

   Open questions at the time

   • Structural basis of the VRK3–VHR interaction not defined
   • Did not establish how VRK3 enhances VHR catalysis mechanistically
2. 2007 Medium

   Confirmed the VHR–VRK3–ERK complex exists in native tissue and is specific to VHR over MKP3, linking the scaffold to physiological EGF-induced ERK signaling.

   Evidence Immunoprecipitation from tissue/embryo lysates and in vitro phosphatase assay with recombinant VRK3

   PMID:18035061

   Open questions at the time

   • Single lab confirmation
   • Tissue-specific functional consequences not tested in vivo
3. 2009 High

   Resolved why VRK3 lacks canonical kinase activity by showing a degraded, ATP-incompetent active site locked in a pseudoactive conformation, while surface conservation supports a protein-interaction role.

   Evidence X-ray crystallography of VRK3/VRK2 with active-site and conservation analysis

   PMID:19141289

   Open questions at the time

   • Crystallized construct lacked the N-terminal regulatory region
   • Structure of VRK3 bound to partners (VHR) not determined
4. 2015 Medium

   Demonstrated residual kinase activity toward BAF/Ser4 via an N-terminal region absent from the crystal, reconciling the pseudokinase structure with a catalytic output that drives BAF relocalization and cell cycle progression.

   Evidence In vitro kinase assay with phospho-specific detection, Ser4 mutagenesis, immunofluorescence, flow cytometry, siRNA

   PMID:25899223

   Open questions at the time

   • Single lab; kinase activity not validated against structural data
   • How the N-terminal region confers catalysis is unresolved
5. 2016 Medium

   Identified an upstream regulatory input by showing CDK5 phosphorylates VRK3 at Ser108 to boost VHR binding and ERK suppression, providing stress-dependent neuroprotection.

   Evidence In vitro CDK5 kinase assay, Co-IP, S108A mutant, siRNA in neurons

   PMID:27346674

   Open questions at the time

   • Single lab
   • Whether Ser108 phosphorylation directly alters the VRK3–VHR interface is unknown
6. 2016 Medium

   Extended the scaffold model by showing VRK3 promotes nuclear HSP70 localization, where HSP70 directly enhances VHR activity to dampen excitotoxic ERK signaling.

   Evidence Co-IP, subcellular fractionation, phosphatase assay, NLS-HSP70 rescue, VRK3-KO neurons

   PMID:27941812

   Open questions at the time

   • Single lab
   • Mechanism by which VRK3 drives HSP70 nuclear import not defined
7. 2017 Low

   Broadened VRK3's cell cycle role through interactome capture of XRCC5 and CCNB1 and depletion phenotypes affecting S phase and G2/M transitions.

   Evidence AP-LC-MS/MS interactomics, biochemical confirmation, flow cytometry, siRNA in liver cancer cells

   PMID:28927264

   Open questions at the time

   • Interactome screen with only partial biochemical confirmation
   • Direct phosphorylation of XRCC5/CCNB1 by VRK3 not demonstrated
8. 2017 Low

   Implicated VRK3 in circadian regulation by showing it reduces nuclear clock-protein abundance and alters rhythm amplitude and period.

   Evidence RFP-tagged clock protein imaging, NLS-mutant VRK3, siRNA with bioluminescence recording

   PMID:28412365

   Open questions at the time

   • No direct binding or phosphorylation of clock proteins shown
   • Mechanism of nuclear clock-protein reduction unknown
9. 2023 Low

   Linked VRK3 to chromatin condensation and VRK1 maintenance in DMG-H3K27M cells, connecting its depletion to G1 arrest and reduced phospho-histone H3.

   Evidence siRNA knockdown, expression profiling, phospho-histone immunoblotting, cell cycle analysis

   PMID:37886173

   Open questions at the time

   • Indirect evidence; no direct histone kinase assay
   • Mechanism of VRK1 protein-level maintenance unresolved

• It remains unknown how VRK3 mechanistically activates VHR at the molecular level and whether its scaffold and residual-kinase functions are coordinated.
• No structure of VRK3 bound to VHR
• Coordination between BAF phosphorylation and ERK-suppression scaffold roles undefined
• In vivo significance of cell cycle and circadian roles untested